Adavosertib联合吉西他滨治疗铂耐药或铂难治性复发性卵巢癌:双盲、随机、安慰剂对照2期试验
这项双盲、随机、安慰剂对照2期试验纳入124例铂耐药或铂难治性复发性卵巢癌女性,其中99例高级别浆液性卵巢癌按2:1随机接受吉西他滨联合Adavosertib或安慰剂,25例非高级别浆液性癌进入非随机探索队列。3级及以上不良事件以血液学毒性为主,中性粒细胞减少62% vs 30%,血小板减少31% vs 6%。结论支持DNA损伤反应药物在TP53突变、高复制压力肿瘤中的进一步评估。
要点
- 适用人群为可测量、复发性铂耐药或铂难治性高级别浆液性卵巢癌,ECOG 0-2、预期寿命>3个月、器官和骨髓功能正常。
- 3级及以上中性粒细胞减少在Adavosertib组为62%(38/61),安慰剂组30%(10/33);血小板减少分别为31%(19/61)和6%(2/33)。
- 两组均无治疗相关死亡;高级别浆液性癌队列中Adavosertib组1例死于脓毒症,安慰剂组1例死于疾病进展。
- 非高级别浆液性卵巢癌患者仅进入非随机探索队列(25例),不参与随机比较。
适用人群与场景
- 纳入:年龄≥18岁、可测量病灶、复发性铂耐药或铂难治性高级别浆液性卵巢癌女性,ECOG体能状态0-2、预期寿命>3个月、器官和骨髓功能正常。
- 非高级别浆液性卵巢癌女性仅纳入非随机探索队列,不参与随机分组。
- 排除:原文未明确列出具体排除标准,仅提及随机后5例高级别浆液性癌患者被发现不符合条件而未接受治疗。
诊断标准与关键阈值
- 铂耐药或铂难治性复发性高级别浆液性卵巢癌的诊断由原文纳入标准界定,未给出具体铂耐药/铂难治的时间界值。
- 可测量病灶为纳入条件之一,具体测量标准原文未提及。
处置流程与药物剂量
- 吉西他滨1000 mg/m2静脉给药,第1、8、15天,每28天为一周期。
- Adavosertib 175 mg口服,每日一次,第1、2、8、9、15、16天,每28天为一周期。
- 对照为安慰剂口服,给药方案与Adavosertib相同,联合吉西他滨1000 mg/m2静脉给药。
- 治疗持续至疾病进展或出现不可接受的毒性。
红旗征与不能漏的情况
- 3级及以上中性粒细胞减少在Adavosertib联合吉西他滨组发生率为62%(38/61),需密切监测血常规。
- 3级及以上血小板减少在Adavosertib联合吉西他滨组发生率为31%(19/61),需监测血小板计数。
- Adavosertib联合吉西他滨组有1例患者在用药期间死于脓毒症。
研究设计与关键结果
- 研究类型:双盲、随机、安慰剂对照2期试验,美国 and 加拿大11个学术中心参与。
- 样本量:124例女性入组,99例高级别浆液性卵巢癌随机分配至Adavosertib联合吉西他滨组(65例,66%)或安慰剂联合吉西他滨组(34例,34%);25例非高级别浆液性癌进入非随机探索队列。
- 安全性:3级及以上中性粒细胞减少62%(38/61)vs 30%(10/33);3级及以上血小板减少31%(19/61)vs 6%(2/33)。
- 无治疗相关死亡;高级别浆液性癌队列中Adavosertib组1例死于脓毒症,安慰剂组1例死于疾病进展。
证据类型、等级与局限
- 证据类型:双盲、随机、安慰剂对照2期试验。
- 局限:2期试验、样本量较小(随机99例)、非高级别浆液性癌为非随机探索队列、随机后5例被判定不符合条件而未治疗、未设分层因素。
对床旁实践的改变
- 在铂耐药或铂难治性高级别浆液性卵巢癌中,Adavosertib联合吉西他滨较安慰剂联合吉西他滨延长无进展生存期,但需注意血液学毒性显著增加。
- 该方案不适用于非高级别浆液性卵巢癌的常规推荐,因该类患者仅进入非随机探索队列。
- 用药期间需密切监测中性粒细胞和血小板计数,警惕脓毒症等严重感染。
- 原文结论认为该联合方案支持DNA损伤反应药物在高复制压力肿瘤中的进一步评估,需更大规模确证性研究。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT02151292。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in patients with ovarian cancer.
METHODS: In this double-blind, randomised, placebo-controlled, phase 2 trial, women with measurable recurrent platinum-resistant or platinum-refractory high-grade serous ovarian cancer were recruited from 11 academic centres in the USA and Canada. Women were eligible if they were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 0-2, a life expectancy of more than 3 months, and normal organ and marrow function. Women with ovarian cancer of non-high-grade serous histology were eligible for enrolment in a non-randomised exploratory cohort. Eligible participants with high-grade serous ovarian cancer were randomly assigned (2:1), using block randomisation (block size of three and six) and no stratification, to receive intravenous gemcitabine (1000 mg/m2 on days 1, 8, and 15) with either oral adavosertib (175 mg) or identical placebo once daily on days 1, 2, 8, 9, 15, and 16, in 28-day cycles until disease progression or unacceptable toxicity. Patients and the team caring for each patient were masked to treatment assignment. The primary endpoint was progression-free survival. The safety and efficacy analysis population comprised all patients who received at least one dose of treatment. The trial is registered with ClinicalTrials.gov, NCT02151292, and is closed to accrual.
FINDINGS: Between Sept 22, 2014, and May 30, 2018, 124 women were enrolled, of whom 99 had high-grade serous ovarian cancer and were randomly assigned to adavosertib plus gemcitabine (65 [66%]) or placebo plus gemcitabine (34 [34%]). 25 women with non-high-grade serous ovarian cancer were enrolled in the exploratory cohort. After randomisation, five patients with high-grade serous ovarian cancer were found to be ineligible (four in the experimental group and one in the control group) and did not receive treatment. Median age for all treated patients (n=119) was 62 years (IQR 54-67). Progression-free survival was longer with adavosertib plus gemcitabine (median 4·6 months [95% CI 3·6-6·4] with adavosertib plus gemcitabine vs 3·0 months [1·8-3·8] with placebo plus gemcitabine; hazard ratio 0·55 [95% CI 0·35-0·90]; log-rank p=0·015). The most frequent grade 3 or worse adverse events were haematological (neutropenia in 38 [62%] of 61 participants in the adavosertib plus gemcitabine group vs ten [30%] of 33 in the placebo plus gemcitabine group; thrombocytopenia in 19 [31%] of 61 in the adavosertib plus gemcitabine group vs two [6%] of 33 in the placebo plus gemcitabine group). There were no treatment-related deaths; two patients (one in each group in the high-grade serous ovarian cancer cohort) died while on study medication (from sepsis in the experimental group and from disease progression in the control group).
INTERPRETATION: The observed clinical efficacy of a Wee1 inhibitor combined with gemcitabine supports ongoing assessment of DNA damage response drugs in high-grade serous ovarian cancer, a TP53-mutated tumour type with high replication stress. This therapeutic approach might be applicable to other tumour types with high replication stress; larger confirmatory studies are required.
FUNDING: US National Cancer Institute Cancer Therapy Evaluation Program, Ontario Institute for Cancer Research, US Department of Defense, Princess Margaret Cancer Foundation, and AstraZeneca.
参考来源
- Lheureux S, Cristea MC, Bruce JP, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021. PMID: 33485453. doi:10.1016/S0140-6736(20)32554-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。